All Neurological disorders articles – Page 9
-
ArticleIL-2 and GLP-1 receptor agonist combination tackles neuroinflammation
Can targeting both regulatory and inflammatory pathways change how we treat neurodegenerative disease? Coya Therapeutics is testing that idea with its IL-2 and GLP-1 receptor agonist combination.
-
NewsBVRA enzyme may slow down Alzheimer’s progression
New research from Johns Hopkins Medicine reveals that the enzyme BVRA protects brain cells from oxidative stress, allowing for potential new methods for treating neurodegenerative diseases like Alzheimer’s.
-
NewsNew blood test detects Alzheimer’s years before symptoms
Scientists have developed two rapid and affordable blood tests that can detect early markers of Alzheimer’s disease – potentially decades before symptoms appear.
-
NewsAlzheimer’s brain structure investigated through fruit flies
Scientists have used fruit flies to study 100 genes linked to Alzheimer’s disease and how these genes affect brain structure, function and stress resilience. The research could help guide new treatments in the future.
-
NewsCRISPR epigenetic ‘switch’ provides new way to control memory
For the first time, researchers have demonstrated that flipping an epigenetic ‘switch’ in memory cells can directly control whether a memory is expressed or silenced, offering new insights into how memories are stored and potentially altered.
-
NewsOveractive neurons linked to schizophrenia-like behaviour
Scientists have identified an overactive brain cell type linked to schizophrenia-like symptoms in mice – a discovery that could lead to new, targeted treatments to prevent cognitive impairments.
-
NewsNew PET tracer could lead to better ALS and Alzheimer’s diagnosis
New preclinical data on ACI-19626, a first-in-class PET tracer for imaging TDP-43 pathology, shows potential to greatly improve early diagnosis and treatment of multiple neurodegenerative diseases.
-
ArticleFrom wild fungi to faster drug discovery
Nature’s pharmacy has yielded half of today’s medicines, yet most of its potential remains untapped. AI is now changing how quickly new therapies can be found.
-
ArticleThe predictive validity crisis: Pharma’s productivity paradox – Part II
Part II shows that the predictive validity crisis can be solved by rethinking how the industry chooses models, measures outcomes and integrates systems. Success stories from Vertex, Regeneron and AstraZeneca illustrate how aligning biology, measurement and strategy can reverse decades of declining productivity.
-
NewsBrain’s circHomer1 RNA offers insights for future neurological treatments
A circular RNA called circHomer1 has been found to play a vital role in forming and adjusting synapses in developing mouse brains, revealing an overlooked mechanism that helps visual neurons respond to changes in sensory input.
-
NewsSPIRAL device offers safer, smarter drug delivery to the brain
Scientists have created a flexible brain implant, called SPIRAL, capable of delivering drugs to multiple regions with pinpoint accuracy.
-
NewsImproving brain resilience: Rab proteins and future treatments
New research has discovered how Rab proteins control the delivery of critical supplies to strengthen neural connections, providing researchers with important insights into memory formation and potential strategies for Alzheimer’s resilience.
-
ArticleThe predictive validity crisis: Pharma’s productivity paradox – Part I
Drug discovery now costs 100 times more per FDA-approved drug than in 1950, despite vast advances in biology and computing. The core problem is the collapse of predictive validity in preclinical models, which sits at the heart of pharma’s productivity paradox.
-
NewsDARG cells may drive neurodegeneration in progressive MS
Scientists have discovered a rare type of brain cell that appears to drive the chronic inflammation seen in progressive multiple sclerosis – which could potentially lead to new disease-modifying therapies.
-
NewsNew gene therapy restores brain function in SYNGAP1 disorder
Scientists have developed a new gene therapy that reversed symptoms of SYNGAP1-related brain disorders in mice, which could lead to new treatments for this group of neurological conditions.
-
ArticleEye movements as objective biomarkers: accelerating CNS drug development
Measuring disease progression remains one of the biggest hurdles in CNS drug development. Eye movements, now trackable with just a laptop and webcam, are emerging as a sensitive and scalable biomarker that could transform how trials are designed and therapies reach patients.
-
NewsDDHD2 enables neurons to synthesise and burn fat for energy
Scientists have discovered that neurons can burn and make their own fats for energy – a finding that could lead to new treatments for rare and currently untreatable brain diseases.
-
NewsNew nanotherapy clears amyloid-β reversing Alzheimer’s in mice
Researchers have developed bioactive nanoparticles that restore the brain’s blood-brain barrier and clear toxic proteins, reversing Alzheimer’s symptoms in mice and offering a promising new approach to treating the disease.
-
NewsScientists track amyloid plaques in living mice for first time
A new fibre-optic method lets researchers monitor amyloid plaque buildup in living, freely moving mice – offering a minimally invasive way to track Alzheimer’s disease progression and test potential therapies.
-
ArticleFighting MS progression: why GPR17 is the target to watch
Despite major advances in multiple sclerosis treatment, stopping disease progression has remained out of reach. Targeting the receptor GPR17 may harness the brain’s own repair system, offering the prospect of genuine remyelination and lasting benefit for patients.